# Harmony Biosciences Reports Record Q2 2026 Revenue of $261M and Shares Initial BP-205 Clinical Data

> news · REPORTED · 2026-08-04

On August 4, 2026, Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3 million, representing 30% year-over-year growth, and simultaneously shared encouraging initial single ascending dose clinical data for its orexin-2 agonist BP-205, described as the most potent OX2R agonist currently in clinical development. The company reaffirmed its full-year 2026 net revenue guidance of $1.0 to $1.04 billion.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences (Nasdaq: HRMY) is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients with central nervous system disorders, led by its marketed product WAKIX (pitolisant) for narcolepsy and a pipeline targeting sleep and neurological conditions.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.biospace.com/press-releases/harmony-biosciences-announces-record-q2-2026-revenue-and-shares-initial-clinical-data-for-its-orexin-2-agonist-bp-205-reinforcing-potential-best-in-class-profile

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.